CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics' stock has been impacted by several key events over the past six months. Positive clinical data for Varseta-M led to a stock rally, followed by a $250 million public offering of common stock. Q4 2025 earnings reported a wider-than-expected loss, but positive Varseta-M data led to a positive market reaction. Q1 2026 earnings beat forecasts, but revenue was down year-over-year. Recent terminations of programs such as CX-904 and CX-2029 have been noted as execution and scientific risks. The stock has experienced significant volatility, with a substantial increase over the past year.

CytomX Therapeutics, Inc. does not have approved products generating direct sales revenue, so demand seasonality is not applicable. Its revenue streams are primarily derived from strategic collaborations, licensing agreements, and milestone payments. The demand for its PROBODY® technology platform is driven by the need for innovative cancer treatments and interest from pharmaceutical companies.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing conditionally activated biologics localized to the tumor microenvironment. The company operates in the Healthcare sector and Biotechnology industry, utilizing its PROBODY® therapeutic technology platform to create safer cancer therapies. Key product candidates include Varsetatug masetecan (Varseta-M), CX-801, CX-904, CX-2029 and BMS-986288. CytomX has strategic collaborations with companies like Amgen, Regeneron, Moderna, and previously Astellas and Bristol Myers Squibb.

CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. Its collaborations with global pharmaceutical companies suggest a broader reach in terms of drug development and potential market access.

CytomX Therapeutics' brand reputation is tied to its scientific advancements and clinical trial progress, particularly with Varseta-M. Positive interim data for Varseta-M and strategic collaborations have positively affected its reputation. Potential challenges include program terminations, clinical trial setbacks, and revenue decline from collaboration completions. The company's reputation is driven by its scientific innovation and pipeline progress.

CytomX Therapeutics, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Major institutional owners include Fmr Llc, VR Adviser, LLC, and Perceptive Advisors Llc. Joseph Edelman owns the most shares of CytomX Therapeutics Inc. Insider ownership is around 0.92%, with recent insider selling activity.